M&A / Deals MSD-backed Ray locks in $125m to back eye drug pipeline Pharmaceutical TechnologyRay's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.M&A / DealsOphthalmologyRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology Ray’s MSD and Novo Holdings-backed Series B will shed light on the potential of the company’s vision restoration gene therapy pipeline. M&A / DealsOphthalmologyRead full story Post navigation Previous: New data build case for Roche’s oral BTK drug for MSNext: FDA delays decision on Sanofi’s subcutaneous Sarclisa Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
